Eledon Pharmaceuticals (ELDN)

• Market cap: $156M
• 1 day: -1.15%
• 5 days: 0.00%
• 1 month: -29.01%
• 3 months: -18.41%
• 6 months: -37.92%
• Year to date: -40.09%
• 1 year: -11.38%
• 5 years: -67.67%
• 10 years: -99.86%
• Sector: Healthcare
• Industry: Biotechnology

About: Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Employees: 31

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 14

2.29% more ownership

Funds ownership: 64.21% [Q1] → 66.5% (+2.29%) [Q2]

1% more funds holding

Funds holding: 83 [Q1] → 84 (+1) [Q2]

8% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 26

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

17% less capital invested

Capital invested by funds: $130M [Q1] → $108M (-$22.4M) [Q2]

61% less call options, than puts

Call options by funds: $88K | Put options by funds: $223K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $9 250% upside
• Avg. target: $10.50 309% upside
• High target: $12 367% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Craig-Hallum	367% upside $12	Buy Initiated	25 Jul 2025
HC Wainwright & Co. Yi Chen	250% upside $9	Buy Assumed	18 Jun 2025